FDA-approved synthetic GHRH analog. 18% visceral fat reduction in 26 weeks. The fat your body refuses to let go of — finally moves.
Visceral fat reduction at 26 weeks (Phase 3)
Approved (as Egrifta) — strongest evidence base in our catalog
Standard cycle length per the Phase 3 protocol
Tesamorelin doesn't suppress your appetite. It does something the GLP-1s can't: it specifically targets visceral adipose tissue — the deep belly fat that wraps around your organs and drives metabolic disease. The kind of fat that's still there after you've lost 30 pounds.
It works by stimulating your pituitary to release growth hormone in a natural, pulsatile pattern. Your body does the rest. Two Phase 3 trials in HIV-associated lipodystrophy demonstrated an average 15–20% reduction in VAT at 26 weeks. The off-label biohacker community has been using it for body composition for over a decade.
You've lost weight but the stubborn belly fat won't budge. You want body recomposition, not just weight loss. You're metabolically healthy enough to handle elevated GH (our intake screens). You're patient — this is a 3–6 month protocol.
You have active cancer or cancer history (GH-axis stimulation is contraindicated). Severe insulin resistance or uncontrolled diabetes. Pituitary disorders or pituitary surgery history. Pregnancy or breastfeeding.
From the Egrifta Phase 3 program. Real outcomes vary; our physician designs your dosing schedule and monitors IGF-1 trajectory.
IGF-1 starts rising into the mid-physiologic range. Subjective energy, sleep quality, and recovery improve.
Measurable visceral fat reduction starts in the published trial population. Waist measurements drop.
15–20% VAT reduction observed in Phase 3 endpoints. Body composition transformation evident.
Standard protocol is 3–4 months on, 1 month off. Your physician designs your maintenance.
Tesamorelin is the only peptide in our catalog with an FDA approval. The Falutz et al. trials (NEJM 2007, JAIDS 2010, JAMA 2014) put it through the same rigor as any pharmaceutical. The evidence is the strongest in our lineup.
Injection-site reactions (redness, mild swelling) · Joint achiness · Peripheral edema · Muscle aches · Mild paresthesia (tingling)
Glucose intolerance · Carpal tunnel symptoms · Fluid retention in cardiac patients · Pituitary suppression on cessation
IGF-1 every 8 weeks to keep you in physiologic range. Fasting glucose at baseline and at 12 weeks. We adjust dose if either trends outside target.
$540.000 COP / 10mg
10-day supply at 1mg/day · MD intake · Shipping included (launch pricing)
$4.600.000 COP / 12 vials
3-month cycle · Monthly MD check-in · Priority shipping · IGF-1 lab orders (launch pricing)
Tesamorelin is FDA-approved (as Egrifta) for HIV-associated lipodystrophy; off-label use is dispensed via magistral compounding under individual physician prescription. Cited percentages reference Falutz et al. 2007/2010 Phase 3 trial endpoints. Not for use in active malignancy, severe insulin resistance, pituitary disorders, pregnancy, or breastfeeding. Discuss your medical history with our physician during intake.